secwatch.observer — SEC 8-K summary
======================================

Issuer:     C4 Therapeutics, Inc. (CCCC)
CIK:        0001662579
Form:       8-K
Filed at:   2025-02-27T23:59:59+00:00
Accession:  0001628280-25-008429
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

C4 Therapeutics reports FY2024 revenue $35.6M, net loss $1.52/sh; cash runway into 2027
--------------------------------------------------------------------------------

- FY2024 revenue $35.6M (vs $20.8M in FY2023); net loss $105.3M ($1.52/sh) vs $132.5M ($2.67).
- Cash $267.3M at Dec 31, 2024; expected to fund operations into 2027.
- Cemsidomide dose escalation continues; next-phase trials expected to start in early 2026.
- CFT1946 Phase 1/2 progressing; data in melanoma and CRC expected H2 2025.
- Appointed Steve Hoerter to board; initiated CFT8919 Phase 1 in Greater China with Betta.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1662579/000162828025008429/0001628280-25-008429-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1662579/000162828025008429/cccc-20250227.htm
  HTML page:      https://secwatch.observer/filing/0001628280-25-008429

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer